Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07810777) titled 'PRA-216 Atopic Dermatitis Safety and Efficacy Study' on Sept. 3.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Prana Therapies Inc
Condition:
Atopic Dermatitis (AD)
Intervention:
Drug: Active PRA-216
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 1, 2026
Target Sample Size: 39
Countries of Recruitment:
Australia
New Zealand
Australia
New Zealand
To know more, visit https://clini...